AU2003275855A1 - Sustained-release tramadol formulations with 24-hour efficacy - Google Patents
Sustained-release tramadol formulations with 24-hour efficacy Download PDFInfo
- Publication number
- AU2003275855A1 AU2003275855A1 AU2003275855A AU2003275855A AU2003275855A1 AU 2003275855 A1 AU2003275855 A1 AU 2003275855A1 AU 2003275855 A AU2003275855 A AU 2003275855A AU 2003275855 A AU2003275855 A AU 2003275855A AU 2003275855 A1 AU2003275855 A1 AU 2003275855A1
- Authority
- AU
- Australia
- Prior art keywords
- hours
- tramadol
- administration
- plasma concentration
- once daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 204
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims description 136
- 238000009472 formulation Methods 0.000 title claims description 97
- 229960004380 tramadol Drugs 0.000 claims description 124
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 123
- 230000036470 plasma concentration Effects 0.000 claims description 94
- 238000013270 controlled release Methods 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 41
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 35
- UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000005259 measurement Methods 0.000 claims description 16
- 230000000202 analgesic effect Effects 0.000 claims description 13
- 238000004090 dissolution Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 3
- 230000037406 food intake Effects 0.000 description 35
- 239000003826 tablet Substances 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 239000008177 pharmaceutical agent Substances 0.000 description 19
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 18
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 18
- 239000002002 slurry Substances 0.000 description 18
- 229920002689 polyvinyl acetate Polymers 0.000 description 17
- 239000011118 polyvinyl acetate Substances 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 16
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 229920001685 Amylomaize Polymers 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 239000002207 metabolite Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 229960003107 tramadol hydrochloride Drugs 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003349 gelling agent Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000008030 elimination Effects 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 229920000856 Amylose Polymers 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000003402 opiate agonist Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- 238000010793 Steam injection (oil industry) Methods 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 2
- 229960003792 acrivastine Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 239000000420 anogeissus latifolia wall. gum Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 2
- 229960004536 betahistine Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 235000019314 gum ghatti Nutrition 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229960005249 misoprostol Drugs 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960003893 phenacetin Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 2
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 2
- 229960004159 pseudoephedrine sulfate Drugs 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 150000003873 salicylate salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 229960005345 trimebutine Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000009807 Cydonia Nutrition 0.000 description 1
- 241001507921 Cydonia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001422 hypoalgesic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960004250 polygeline Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940054370 ultram Drugs 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
WO 2004/037222 PCT/CA2003/001638 SUSTAINED-RELEASE TRAMADOL FORMULATIONS WITH 24-HOUR EFFICACY FIELD OF THE INVENTION 5 [0001]This invention relates to a novel once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof. BACKGROUND OF THE INVENTION Tramadol Pharmaceutical Formulations [0002]Tramadol hydrochloride (HCI) was developed by GrOnenthal GmbH, Germany. 10 It has been marketed in Germany since 1977 (eg. Trama T M ), and in the United States as Ultram® since 1995. The efficacy and safety profile of tramadol HCI make it highly suitable as a long-term treatment for chronic pain. [0003]Tramadol HCI is a synthetic, centrally acting analgesic that has been shown to be effective in a variety of acute and chronic pain states. In particular, tramadol HCI, 15 in both immediate and slow-release formulations, in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) (Roth SH. "Efficacy and safety of tramadol HCI in breakthrough musculoskeletal pain attributed to osteoarthritis". J. Rheumatol 1998; 25:1358-1363. Wilder-Smith CH et al. "Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a 20 randomized study comparing analgesia, antinociception and gastrointestinal effects". Pain 2001; 91:23-31.), has been demonstrated to reduce pain attributed to osteoarthritis (OA). After oral administration, tramadol HCI is rapidly and almost completely absorbed, and it is extensively metabolized. The major metabolic pathways appear to be N- and O- demethylation and glucuronidation or sulfonation in 25 the liver. Only one metabolite, mono-O-desmethyltramadol (Ml), is pharmacologically active, which has an approximate 200-fold higher affinity for the /J opioid receptor than racemic tramadol (DeJong R. "Comment on the hypoalgesic effect of tramadol in relation to CYP2D6" (comment) Pain Dig 1997; 7:245; Kogel B. et al "Involvement of metabolites in the analgesic action of tramadol" Proc. 9 th World 30 Congress on Pain, Vienna, 1999). In healthy humans, tramadol is demethylated by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6) to the M1 metabolite. 1 WO 2004/037222 PCT/CA2003/001638 [0004]The mechanism of action of tramadol HCI is not completely understood. Animal models indicate that the drug (and its active M1 metabolite) acts as an opiate agonist, apparently by selective activity at the p-receptor. In addition to opiate agonist activity, tramadol HCI inhibits re-uptake of certain monoamines 5 (norepinephrine, serotonin) which appears to contribute to the drug's analgesic effect. The antinociceptic effect of tramadol HCI is only partially antagonized by naloxone in some tests in animals and humans. In addition, because of the drug's opiate agonist activity, it has been suggested that tramadol HCI may produce dependence; however, its abuse potential appears to be low, and tramadol HCI is not "subject to 10 control" under the United States Federal Controlled Substances Act of 1970 as a scheduled drug. [0005]Immediate release formulations of tramadol HCI are well known in the art. Such formulations, however, require frequent dosing in order to provide effective pain relief. Lack of compliance with high frequency dosing regimens can result in 15 inconsistent plasma drug concentrations and accordingly less consistent analgesia. Twice daily formulations are available and are desirable over immediate release formulations as they provide longer periods of analgesia after administration and require less frequent dosing. A once daily formulation is even more desirable for increased effectiveness, safety and convenience. 20 [0006]A critical factor influencing the rate of absorption, and thereby the safety and efficacy, of an active pharmaceutical ingredient by the body following oral administration in a tablet or other solid dosage form is the rate of release of the active pharmaceutical ingredient from that dosage form post ingestion. [0007] It is thus the ability of the dosage form components to control the release rate 25 that constitutes the basis for the so-called controlled-release, extended-release, sustained-release or prolonged-action pharmaceutical preparations that are designed to produce slow, uniform release and absorption of active pharmaceutical ingredients over a period of hours, days, weeks or months. The advantages of such controlled release formulations include: a reduction in the required administration frequency of 30 the drug as compared to conventional immediate release dosage forms, often resulting in improved patient compliance; the maintenance of a stable concentration of the drug in the body and thereby a sustained therapeutic effect over a set period of time; and a decreased incidence and intensity of undesired side effects of the active 2 WO 2004/037222 PCT/CA2003/001638 agent caused by the high plasma concentrations that occur after administration of immediate-release dosage forms. [0008]Many materials have been proposed and developed as matrices for the controlled release of active pharmaceutical ingredients. These include, for example, 5 polymeric materials such as polyvinyl chloride, polyethylene amides, ethyl cellulose, silicone and poly (hydroxymethyl methacrylate). See e.g., U.S. Patent No. 3,087,860 to Endicott et aL.; U.S. Patent No. 2,987,445 to Levesque et aL; Salomon et aL. Pharm. Acta Helv., 55, 174-182 (1980); Korsmeyer, Diffusion Controlled Systems: Hydrogels, Chap. 2, pp 15-37 in Polymers for Controlled Drug Delivery, Ed Tarcha, 10 CRC Press, Boca Raton, Fla. USA (1991); and Buri etaL, Pharm. Acta Helv. 55,189 197 (1980). [0009] High amylose starch has also been used for controlled-release purposes and, in particular, recent advances have been made using cross-linked high amylose starch. For example, United States Patent No. 6,284,273 (Lenaerts et aL.), which 15 issued September 4, 2001, and No. 6,419,957 (Lenaerts et aL.), which issued July 16, 2002, teach a solid controlled release oral pharmaceutical dosage unit in the form of tablets comprising a dry powder of a pharmaceutical product and a dry powder of cross-linked high amylose starch, wherein said cross-linked high amylose starch is a matrix comprising a mixture of about 10-60% by weight of amylopectin and about 40 20 90% amylose. United States Patent No. 6,607,748 (Lenaerts et aL.) which issued on August 19, 2003 describes a process for making a cross-linked high amylose starch which is known under the name Contramid®. Extended Release Formulations Known in the Art [0010]Extended and controlled release formulations relating to tramadol HCI have 25 been suggested, examples being described in: United States Patent Application Publication No. 2003/0143270, (Deboeck et aL.) published July 31, 2003; United States Patent No. 6,254,887 (Miller et aL) issued July 3, 2001; United States Patent Application Publication No. 2001/0036477 (Miller et aL.) published November 1, 2001; United States Patent No. 6,326,027 (Miller et aL.) issued December 4, 2001; and 30 United States Patent No. 5,591,452 (Miller et al) issued January 7, 1997; and European Patent No. 1 190 712 (Vanderbist) published March 27, 2002. 3 WO 2004/037222 PCT/CA2003/001638 [0011]Although there are some controlled release tramadol HCI formulations on the market which purport to be once-daily formulations, none of these has successfully replaced twice-daily tramadol HCI formulations. [0012]Articles have been published in which comparative data between putative 5 "once-daily" tramadol HCI formulations and immediate release tramadol HCI formulations are presented: Adler et aL., "A Comparison of Once-Daily Tramadol with Normal Release Tramadol in the Treatment of Pain in Osteoarthritis," The Journal of Rheumatology (2002) 29(10): 2195-2199; and Bodalia et aL, "A Comparison of the Pharmacokinetics, Clinical Efficacy, and Tolerability of Once-Daily Tramadol Tablets 10 with Normal Release Tramadol Capsules," Journal of Pain and Symptom Management (2003) 25(2): 142-149. Adverse Events from Administration of Tramadol HCI [0013]The most frequently reported side effects of tramadol observed in clinical trials in the United States are constipation, nausea, dizziness/vertigo, headache, 15 somnolence and vomiting. These are typical adverse effects of opiate drugs. Seizures and anaphylactoid reactions have also been reported, though the estimated incidence of seizures in patients receiving tramadol HCI is less than 1% (Kazmierczak, R., and Coley, K.: "Doctor letters on prescribing: evaluation of the use of tramadol HCI." Formulary 32: 977-978, 1997). 20 [0014]Adler et aL., supra, reports on the results of a clinical study comparing a once daily tramadol formulation to immediate release tramadol in the treatment of pain in osteoarthritis. The authors report similar adverse event profiles for individuals in both treatment groups. Table 2 of Adler et aL indicates that a greater percentage of people who were in the once daily treatment group withdrew due to adverse events 25 than did those in the other treatment group. [0015]ln Bodalia et al., supra, the authors report comparable tolerability with a 150 mg once daily dose, a 200 mg once daily dose and three doses of a 50 mg normal release tramadol formulation. This article does not however include any information on how to make the formulations which are purported to be "once daily" nor does the 30 article disclose any pharmacokinetic data after a single dose. [0016]Citation or identification of any reference in this section shall not be construed as an admission that such reference is available as prior art to the present invention. 4 WO 2004/037222 PCT/CA2003/001638 SUMMARY OF THE INVENTION [0017]An object of the present invention is to provide an improved sustained-release tramadol formulation with 24-hour effective analgesia. [0018]ln accordance with one aspect of the present invention, there is provided a 5 once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, in which the composition, upon initial administration, provides an onset of analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration. [0019] In accordance with another aspect of the present invention, there is provided a 10 once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 100 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 100 ng/mL for at least 22 hours after administration. 15 [0020] In an embodiment of the present invention, there is provided a once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 100 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 100 ng/mL for at least 20 22 hours after administration and wherein the mean maximum plasma concentration (Cmax) is less than 2.2 times the mean plasma concentration obtained 24 hours after administration (C24h). [0021]The term "Xz" is the apparent terminal elimination rate constant, determined by the slope of the regression during the log-linear phase. 25 [0022]The term "AUCo-Tmax" is the mean area under the plasma concentration-time curve from time 0 to Tmax and is used as an indicator of the rate of drug absorption, or metabolite formation. It is calculated as the arithmetic mean of the area under the plasma concentration-time curve from time 0 to Tmax calculated for each individual participating in the bioavailability study. 30 [0023]The term "AUC 0 -." is the mean area under the plasma concentration-time curve extrapolated to infinity. It is calculated as the arithmetic mean of the area under 5 WO 2004/037222 PCT/CA2003/001638 the plasma concentration-time curve from time 0 extrapolated to infinity, calculated for each individual participating in the bioavailability study. [0024]The term "analgesic effect" is defined for the purposes of the present invention as providing a mean blood plasma concentration of at least about 100 ng/mL of 5 tramadol. [0025]The term "C'max" is the maximum observed plasma concentration, calculated as the mean of the individual maximum blood plasma concentrations. [0026] The term "controlled release" is defined for purposes of the present invention as a method of oral drug delivery where the rate of release of the active 10 pharmaceutical ingredient from the formulation is not solely dependent on the concentration of active pharmaceutical ingredient remaining in the formulation and/or the solubility of the active pharmaceutical ingredient in the medium surrounding the formulation, and where the time course and/or location of release of an active ingredient from a pharmaceutical formulation are chosen to accomplish therapeutic or 15 convenience objectives not offered by conventional dosage forms. [0027] The term "half-life" is the apparent terminal elimination half-life. [0028]The term "HVD" is the half value duration, that is, the time during which tramadol concentrations are above one half the C'max. This parameter is an indicator of the shape of the plasma concentration time curve. 20 [0029]The term "immediate release" is defined for purposes of the present invention as the release of an active ingredient from a pharmaceutical formulation where the rate of release of the active pharmaceutical ingredient from the pharmaceutical formulation is not retarded by means of a controlled release matrix and where the components of the pharmaceutical formulation are designed such that, upon 25 ingestion, maximum exposure of said active pharmaceutical ingredient to body tissues occurs in the minimum period of time. [0030]The term "initial administration" is defined for purposes of the present invention as the first single dose of a formulation containing an active ingredient administered to a patient or subject or the first dose administered to a patient or subject after a 30 suitable washout period. 6 WO 2004/037222 PCT/CA2003/001638 [0031]The term "MRT" is the mean residence time, which is an estimate of the average time that a tramadol molecule resides in the body following oral administration. [0032]The term "mean maximum plasma concentration" (Cmax) is defined for the 5 purposes of the present invention as the maximum mean plasma concentration. [0033]The term "mean plasma concentration" is defined for purposes of the present invention as the arithmetic mean blood plasma concentration. 0026a] [0034]The term "tmax" is the time at which Cmax is achieved. [0035]The term "Tmax " is the time at which the maximum blood plasma concentration 10 is observed for each individual participating in the bioavailability study. [0036]The term "Rstart" is the time at which plasma concentrations begin to decline in a log-linear fashion, that is, the time at which either drug absorption or metabolite formation is complete. [0037]The word "tramadol", as used herein shall refer to tramadol, its stereoisomers 15 and its pharmaceutically acceptable salts. [0038]The term "steady state" is defined for purposes of the present invention as the state, following multiple dose administration, where the rate of drug elimination matches the rate of input and the plasma drug concentrations at a given time within a dosing interval are approximately the same from one dosing interval to another. 20 BRIEF DESCRIPTION OF THE FIGURES [0039]Various features and advantages of the present invention will become clear from the more detailed description given below with reference to the accompanying drawings, in which: [0040] Figure 1: Flow diagram showing manufacturing process for tablets. 25 [0041]Figure 2: Dissolution profiles of formulations A, B and C: In vitro performance of formulations A, B and C: under USP Type 1 Conditions; sodium phosphate buffer, 50 mM, pH 6.8, 100 rpm. 6 tablets were tested per time point. [0042]Figure 3: Mean tramadol plasma concentrations following single-dose administration of (i) a 100 mg dose of the inventive controlled release composition 7 WO 2004/037222 PCT/CA2003/001638 (*), (ii) a 200 mg dose of the inventive controlled release composition (m), and (iii) a 300 mg dose of the inventive controlled release composition (A). [0043]Figure 4: Mean O-desmethyltramadol plasma concentrations of following single dose administration of either 100 mg (+), 200 mg (0), and 300 mg (A) 5 strength tramadol formulations (A, B, and C, respectively). [0044]Figure 5: Mean tramadol plasma concentrations following single-dose administration of (i) 2 x 200 mg doses of the inventive controlled release composition (A); and (ii) Topalgic@ LP 200 mg BID q12h (A). [0045]Figure 6: Mean O-desmethyltramadol plasma concentrations following 10 single-dose administration of (i) 2 x 200 mg doses of the inventive controlled release composition (A); and (ii) Topalgic@ LP 200 mg BID q12h (A). [0046]Figure7: Mean steady-state tramadol and O-desmethyltramadol plasma concentration following administration of (i) a 200 mg dose of the inventive controlled release composition (* & o); and (ii) Topalgic@ LP 100 mg BID q12h (A & A). 15 DETAILED DESCRIPTION OF THE INVENTION CORE [0047]The core of a tablet of the invention includes at least one active ingredient and a matrix, these components associated in such a way that release of the pharmaceutical ingredient from the matrix is controlled. In a specific embodiment, 20 the matrix of the core is a cross-linked high amylose starch known under the name Contramido, and described most recently in U.S. Patent No. 6,607,748 (Lenaerts et al.), which issued August 19, 2003. A preferred formulation in the context of this invention is provided in the specification of U.S. Patent No. 6,607,748. [0048]Preferably, the core is formed by admixing the ingredients (in granular or 25 powder form) and then compressing the mixture to form the core over which the coat is subsequently formed. The weight of the core can be any percentage of the weight of the total composition between 10% and 80%. The preferred percentage depends, upon other things, the total dosage of the pharmaceutical agent. In a particular embodiment described further below, a tablet contains 100 mg tramadol 30 hydrochloride and the core is about 26% of the total weight of the tablet. In another embodiment, a tablet contains 200 mg tramadol hydrochloride and the core makes 8 WO 2004/037222 PCT/CA2003/001638 up about 33% of the total weight of the tablet. In yet another embodiment, a tablet contains 300 mg tramadol hydrochloride, and the core contributes 33% to the total weight of the tablet. Active Agent in the Core 5 [0049]An active pharmaceutical ingredient is present in the core of the composition of the present invention. A suitable pharmaceutical ingredient of the present invention is any such ingredient that is desired to be delivered in a sustained-release dosage form. A comprehensive list of suitable pharmaceutical agents can be found in The Merck Index, 12 1h Ed. Preferably, the pharmaceutical ingredient is, but not 10 limited to, isonicotinic acid hydrazide, sodium salicylate, pseudoephedrine hydrochloride, pseudoephedrine sulfate, acetaminophen or diclofenac sodium, verapamil, glipizide, nifedipine, felodipine, betahistine, albuterol, acrivastine, omeprazole, misoprostol, tramadol, oxybutynin, trimebutine, ciprofloxacin, and salts thereof. In addition, the pharmaceutical agent can be an antifungal agent, such as 15 ketoconazole, or an analgesic agent such as acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen, ketoprofen, indomethacin, diflunisal, naproxen, ketorolac, diclofenac, tolmetin, sulindac, phenacetin, piroxicam, mefamanic acid, dextromethorphan, other non-steroidal anti-inflammatory drugs including salicylates, pharmaceutically acceptable salts thereof or mixtures thereof. Pro-drugs are part of 20 the invention. [0050]The solubility of the pharmaceutical agent in aqueous solution can be a wide variety of values. The aqueous solubility of the pharmaceutical agent can be less than 10 3 g/L, more than 10 3 g/L, more than 10-2 g/L, more than 10
"
1 g/L, more than 1 g/L, more than 10 g/L, more than 100 g/L, more than 500 g/L, more than 1000 g/L, 25 or more than 2000 g/L. Preferably, the solubility is more than 100 g/L. More preferably, the solubility is more than 500 g/L. Most preferably, the solubility is more than 1000 g/L. [0051]The pharmaceutical agent can meet a variety of dosage requirement. For example, the dosage requirement of the pharmaceutical agent can be less than 1 30 mg/dosage unit, more than 1 mg/dosage unit, more than 10 mg/dosage unit, more than 100 mg/dosage unit, more than 200 mg/dosage unit, more than 300 mg/dosage unit, more than 400 mg/dosage unit, more than 500 mg/dosage unit, or more than 9 WO 2004/037222 PCT/CA2003/001638 1000 mg/dosage unit. Preferably, the pharmaceutical agent is more than 50 mg/dosage unit. More preferably, the pharmaceutical agent is 100 mg/dosage unit, or more, e.g. 150 mg/dosage unit, or 200 mg/dosage unit, or 250 mg/dosage unit, or 300 mg/dosage unit, or more. 5 [0052]Particular embodiments include a core containing tramadol hydrochloride in which the core contains between about 10% and 90% of the total tramadol present in the tablet, e.g. about 45 mg of a 100 mg strength tablet (45% of the tablet total), or about 90 of a 200 mg strength tablet (45% of the tablet total), or about 151 mg of a 300 mg strength tablet (50% of the tablet total). 10 Matrix of the Core [0053]The release from the formulation of an active pharmaceutical ingredient located in the core is slower than the release of an active pharmaceutical ingredient located in the matrix of the coat. A preferred matrix of the core is cross-linked high amylose starch, known under the name Contramide and described in U.S. Patent No. 15 6,607,748. In particular embodiments, the matrix makes up between about 10% and about 90% by weight of the core i.e., the ratio of the matrix of the core to the active ingredient of the core (w/w) is between about 0.1 and about 10, or between about 0.2 and about 9, or between about 0.2 and about 8, or between about 0.3 and about 7, or between about 0.4 and about 6, or between about 0.5 and about 5, or between about 20 0.6 and about 4, or between about 0.7 and about 4 or between about 1 and about 4, or between about 1 and about 3 and about 1.5 and about 2.5. In one particular embodiment, the core totals about 90 mg, of which about 44 mg is Contramid®, and 45 mg is tramadol hydrochloride. In this case, Contramide thus makes up about 49 weight percent of the core. 25 Optional Components [0054]The core composition of the present invention may optionally include a pharmaceutically acceptable carrier or vehicle. Such carriers or vehicles are known to those skilled in the art and are found, for example, in Reminqtons's Pharmaceutical Sciences, 14 th Ed. (1970). Examples of such carriers or vehicles 30 include lactose, starch, dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar. Additionally, when required, suitable binders, lubricants, and 10 WO 2004/037222 PCT/CA2003/001638 disintegrating agents can be included. If desired, dyes, as well as sweetening or flavoring agents can be included. [0055]The core composition of the present invention may optionally include accessory ingredients including, but not limited to dispersing agents such as 5 microcrystalline cellulose, starch, cross-linked starch, cross-linked poly(vinyl pyrrolidone), and sodium carboxymethyl cellulose; flavoring agents; coloring agents; binders; preservatives; surfactants and the like. [0056]The core can, optionally, also include one or more suitable binders known to one of ordinary skilled in the art. 10 [0057]Suitable forms of microcrystalline cellulose, for example, MCC-PH101, MCC 102, MCC-105, etc. [0058]Suitable lubricants, such as those known to the skilled person, may also be included. For example, magnesium stearate, vegetable oil, talc, sodium-stearyl fumarate, calcium stearate, stearic acid, etc. 15 [0059]Suitable glidants, known in the art, may also be included. Examples of such glidants include, but are not limited to talc, colloidal silicon dioxide, etc. Proportion [0060]The active agent is present at levels ranging from about 1 to about 90 wt.% of the total weight of the core, preferably from about 10 to about 70 wt.% of the total 20 composition of the core, more preferably from about 20 to about 60 wt.% of the total composition of the core, and probably most often between about 30 to about 50 wt.% of the total composition of the core. [0061]Of course, the total amount of all components is 100wt.%, and those of ordinary skill in the art can vary the amounts within the stated ranges to achieve 25 useful compositions. COAT [0062]The coat of the dosage form includes a physical mixture of polyvinyl acetate and polyvinylpyrrolidone and the active pharmaceutical ingredient(s) of the coat. The coat can also include a cross-linked high amylose starch, e.g., Contramido, and other 30 optional components. In a preferred embodiment, the coat is formed by dry compression. The weight of the coat can be any percentage of the weight of the total 11 WO 2004/037222 PCT/CA2003/001638 composition between about 10% and about 90%, but is preferably in the higher part of this range. The coat thus usually makes up between about 20% to about 90%, (w/w) of a tablet of the invention, or about 25% to about 90%, or about 30% to about 85%, or about 35 % to about 85%, or about 40% to about 85%, or about 45% to 5 about 85%, or about 45% to about 90%, or about 50% to about 90% or about 50% to about 85 %, or about 55% to about 90%, or about 55% to about 85%, or about 55% to about 80%, or about 60% to about 90%, or about 60% to about 85%, or about 60% to about 80%, or about 60% to about 75%, or about 65% to about 90%, or about 65% to about 85%, or about 65% to about 80%, or about 65% to about 75%, or about 65% 10 or about 70% or about 75%. The coat often includes an optional binding agent. Polyvinyl Acetate and Polyvinylpyrrolidone of the Coat [0063]The weight percentage of the polyvinyl acetate/polyvinylpyrrolidone mixture in the coat can be anywhere within a wide range of values. Depending on the solubility 15 in water of the active ingredient in the coat, the amount of the polyvinyl acetate/polyvinylpyrrolidone mixture in the coat can be adjusted. United States Patent Publication No. 2001/0038852 describes ways in which such adjustments can be made. For example, for active ingredients that are soluble to extremely soluble in water, polyvinyl acetate/polyvinylpyrrolidone mixture can be about 20 to about 20 80 wt.% of the coat, preferably about 30 to about 65 wt.%, or about 40 to about 55 wt.%. In a particular embodiment described below, KollidonTM SR makes up about 45% by weight of a coat that is about 31% by weight tramadol hydrochloride and about 23% xanthan gum. For active ingredients that are sparingly soluble to slightly soluble in water, the amount of polyvinyl acetate/polyvinylpyrrolidone mixture 25 is often lower, as described in United States Patent Publication No. 2001/0038852. [0064]The weight ratio of polyvinyl acetate to polyvinylpyrrolidone in the polyvinyl acetate/polyvinylpyrrolidone mixture can be a wide range of values. Preferably, such ratio is between about 6:4 and 9:1; more likely between about 7:3 and 6:1, even more preferably about 8:2. 30 [0065]The molecular weight of the polyvinyl acetate component in the polyvinyl acetate/polyvinylpyrrolidone mixture can be a wide range of values. Preferably, the average molecular weight of the polyvinyl acetate is about 100 to about 10,000,000; 12 WO 2004/037222 PCT/CA2003/001638 or about 1,000 to about 1,000,000; or about 10,000 to about 1,000,000; or about 100,000 to about 1,000,000; or about 450,000. [0066]The molecular weight of the polyvinylpyrrolidone component in the polyvinyl acetate/polyvinylpyrrolidone mixture can be a wide range of values. The average 5 molecular weight of the polyvinylpyrrolidone can be from about 100 to about 10,000,000; or about 1,000 to about 1,000,000; or about 5,000 to about 500,000; or about 10,000 to about 100,000; or about 50,000. [0067]The polyvinyl acetate and polyvinylpyrrolidone mixture can be prepared by a variety of processes including simply mixing powders of polyvinylpyrrolidone and 10 polyvinyl acetate. In a preferred embodiment, such mixture is spray dried powder of a colloidal dispersion of polyvinyl acetate and polyvinylpyrrolidone solution. Optionally, sodium lauryl sulfate is used as a stabilizer in order to prevent agglomeration during spray drying process and/or colloidal silica is used to improve the flow properties of the polyvinyl acetate/polyvinylpyrrolidone mixture. Optionally, 15 polyvinyl acetate and polyvinylpyrrolidone can be formed in a random or a block copolymer. Optional Components [0068] Suitable binding agents for the present invention include, but are not limited to, plant extracts, gums, synthetic or natural polysaccharides, polypeptides, alginates, 20 synthetic polymers, or a mixture thereof. [0069] Suitable plant extracts to be used as gelling agents include, but are not limited to, agar, ispaghula, psyllium, cydonia, ceratonia or a mixture thereof. [0070]Suitable gums to be used as gelling agents include, but are not limited to, xanthan gum, guar gum, acacia gum, ghatti gum, karaya gum, tragacanth gum or a 25 mixture thereof. [0071] Suitable synthetics or natural hydrophilic polysaccharides to be used as gelling agents include, but are not limited to, hydroxyalkylcelluloses, cellulose ethers, cellulose esters, nitrocelluloses, dextrin, agar, carrageenan, pectin, furcellaran, starch or starch derivatives, cross-linked high amylose starch, or a mixture thereof. 30 [0072]Suitable polypeptides to be used as gelling agents include, but are not limited to, gelatin, collagen, polygeline or a mixture thereof. 13 WO 2004/037222 PCT/CA2003/001638 [0073]Suitable alginates to be used as gelling agents include, but are not limited to, alginic acid, propylene glycol alginate, sodium alginate or a mixture thereof. [0074]Suitable synthetic polymers to be used as gelling agents include, but are not limited to, carboxyvinyl polymer, polyvinyl alcohol, polyvinyl pyrrolidone, polyethelene 5 oxide, polyethylene glycols, copolymers of ethylene oxide and propylene oxide and their copolymers or a mixture thereof. [0075]In a preferred embodiment, the gelling agent is a gum such as xanthan gum, guar gum, acacia gum, ghatti gum, karaya gum, tragacanth gum or a mixture thereof, PEO 7,000,000 and HPMC K100 M. 10 [0076] In a most preferred embodiment, the gelling agent is xanthan gum. Active agent of the Coat [0077]A suitable active pharmaceutical ingredient of the present invention is any active agent that it is desired to be delivered in a sustained-release dosage form. A comprehensive list of suitable pharmaceutical agents can be found in The Merck 15 Index, 12 th Ed. Preferably, the pharmaceutical agent is, but not limited to, isonicotinic acid hydrazide, sodium salicylate, pseudoephedrine hydrochloride, pseudoephedrine sulfate, acetaminophen or diclofenac sodium, verapamil, glipizide, nifedipine, felodipine, betahistine, albuterol, acrivastine, omeprazole, misoprostol, tramadol®, oxybutynin, trimebutine, ciprofloxacin, and salts thereof. In addition, the 20 pharmaceutical agent can be an antifungal agent, such as ketoconazole, or an analgesic agent such as acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen, ketoprofen, indomethacin, diflunisal, naproxen, ketorolac, diclofenac, tolmetin, sulindac, phenacetin, piroxicam, mefamanic acid, dextromethorphan, other non-steroidal anti-inflammatory drugs including salicylates, pharmaceutically 25 acceptable salts thereof or mixtures thereof. [0078]The solubility of the pharmaceutical agent in aqueous solution can be a wide variety of values. The aqueous solubility of the pharmaceutical agent can be less than 10- 3 g/L, more than 10
-
3 g/L, more than 10 - 2 g/L, more than 101 g/L, more than 1 g/L, more than 10 g/L, more than 100 g/L, more than 500 g/L, more than 1000 g/L, 30 or more than 2000 g/L. Preferably, the solubility is more than 100 g/L. More preferably, the solubility is more than 500 g/L. or even 1000 g/L. 14 WO 2004/037222 PCT/CA2003/001638 [0079]The pharmaceutical agent can meet a variety of dosage requirements. For example, the dosage requirement of the pharmaceutical agent can be less than 1 mg/dosage unit, more than 1 mg/dosage unit, more than 10 mg/dosage unit, more than 100 mg/dosage unit, more than 200 mg/dosage unit, more than 300 mg/dosage 5 unit, more than 400 mg/dosage unit, more than 500 mg/dosage unit, or more than 1000 mg/dosage unit. Preferably, the pharmaceutical agent is more than 50 mg/dosage unit. More preferably, the pharmaceutical agent is more than 100 mg/dosage unit. Most preferably, the pharmaceutical agent is more than 200 mg/dosage unit. 10 [0080]The coat can be between about 5% and about 90% by weight active pharmaceutical ingredient, or between about 5% and about 80% by weight api, or between about 10% and about 70% by weight api, or between about 10% and about 60% by weight api, or between about 15% and about 50% by weight api, or between about 15% and about 45% by weight api, or between about 15% and about 40% by 15 weight api, or between about 20% and about 35% by weight api, or between about 20% and about 30% by weight api. [0081][n particular embodiments, described further below, the weight of tramadol from a 100 mg tramadol tablet is about 21% by weight of the coat. The weight of tramadol from a 200 mg tablet is about 31 % by weight of the coat. The weight of 20 tramadol from a 300 mg tablet is about 30% by weight of the coat. ROUTES OF ADMINISTRATION [0082]The tablet composition of the present invention can be administered through, but not limited to, a number of routes such as oral, sublingual, and rectal. The preferred route of administration of the compositions of the present invention is oral. 25 [0083]Compositions of the present invention that are suitable for oral administration may be presented as discrete units such as tablets or granules. Preferably, the compositions of the present invention are presented in a tablet form. Such tablets may be conventionally formed by compression or molding. Compressed tablets may be prepared by compressing in a suitable machine the mixture of one or more 30 components described above. Molded tablets may be made by molding in a suitable machine the above components, which can be optionally moistened with an inert liquid diluent. The tablets may optionally be coated and/or have other identifying indicia visible to the consumer. A tablet can also be in a variety of forms, 15 WO 2004/037222 PCT/CA2003/001638 e.g., uncoated , dry coated, or film coated, etc. A tablet can also be in a variety of shapes (e.g., oval, sphere, etc.) and sizes. A comprehensive discussion of tablets can be found in references such as The Theory and Practice of Industrial Pharmacy by Lachman et aL, 3 rd Ed. (Lea & Febiger, 1986). 5 Dissolution Profile of Sustained-Release Composition [0084]The active agent of the composition exhibits the following in vitro dissolution 10 profile when measured with a USP Type I apparatus in 50 mM phosphate, pH 6.8, and stirring between 50 and 150 rpm: an average rate of between 10% and 30% per hour of the agent is released between 0 and 2 hours when tested in vitro using a USP Type I apparatus in 50 mM phosphate, pH 6.8, and stirring between 50 and 150 rpm; or 15 between 10% and 40% of the agent is released from the formulation between 0 and about 2 hours of measurement, between about 30% and 60% of the agent is released from the formulation between 2 and about 7 hours of the measurement, between about 50% and 80% of the agent is released from the formulation between 7 and about 12 hours of measurement, and between about 80% and 100% of the 20 agent is released from the formulation after about 20 hours of measurement; or more preferably between 15% and 35% of the agent is released from the formulation between at 2 hours of measurement, between about 40% and 60% of the agent is released from the formulation between at 7 hours of the measurement, between about 60% and 25 80% of the agent is released from the formulation at 12 hours of measurement, and between about 85% and 100% of the agent is released from the formulation after about 20 hours of measurement, or between 20% and 40% of the agent is released from the formulation between at 2 hours of measurement, between about 40% and 60% of the agent is released from 30 the formulation between at 7 hours of the measurement, between about 60% and 80% of the agent is released from the formulation at 12 hours of measurement, and 16 WO 2004/037222 PCT/CA2003/001638 between about 85% and 100% of the agent is released from the formulation after about 20 hours of measurement. [0085]The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its 5 scope. EXAMPLES [0086]The cross-linked high amylose starch used in the these examples is made by a process comprising the steps of crosslinking and chemically modifying, followed by gelatinization and drying. Such process is described in more detail in U.S. Patent 10 No. 6,607,748 (Lenaerts et al.), which issued August 19, 2003, and known in the marketplace under the name Contramid®. and described in Examples 1 and 2. Example 1 A. Cross-Linking [0087]High amylose starch (30.0 kg) containing about 70% w/w of amylose (Cl 15 AmyloGel 03003) is placed in a reactor. To this reactor is added water (55.0 1) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 300C. Phosphorus oxychloride (22.5 g) is added to the reaction mixture which is reacted for one hour. B. Chemical Modification, Hydroxyproylation 20 [0088] The crude reaction mixture from Part A is transferred into a hydroxypropylation reactor. The reaction mixture is heated to 400C. over 30 minutes and the reaction is purged with nitrogen. After a full purge, propylene oxide (1.80 kg) is added. The reaction mixture is kept at 400C. for 20 hours. The reaction mixture is neutralized with 0.1N H 2
SO
4 (1:2 v/v) to a pH of 5.5. The starch slurry is washed with 25 a basket-centrifuge at a speed of 1200 rpm. The obtained starch cake is re-slurrified in 35 I of water and centrifuged a second time. The resulting starch cake is dried in a flash dryer at an inlet temperature of 1600C. and an outlet temperature of 600C. 30 C. Gelatinization [0089]The modified granular starch cake is diluted in demineralized water in order to form a slurry at a concentration of about 8% calculated on dry substance. The resulting slurry has a relative density of 1.032 kg/I compared to water. The pH of the 17 WO 2004/037222 PCT/CA2003/001638 modified starch slurry is adjusted to 6.0. The slurry is then heated to 1600C. by direct steam injection (Schlick Model 825). The temperature variation is not higher than ±10C. The slurry is held in a holding column for a period of 4 minutes at a temperature of 1600C. and a pressure of about 5.5 bar. The pressure is then 5 reduced to atmospheric by passing through a flash. The slurry is then contained at 950C. in a hold tank. D. Spray-Drying [0090]The drying of the slurry from Part C is carried out using a Niro FSD 4 spray drying tower equipped with a 0.8 mm nozzle and fed at 10 I/hour. The inlet 10 temperature is fixed at 3000C. and the outlet temperature of 1200C. The obtained powder is a controlled release excipient with the following properties: Properties Moisture Content 4.5% Bulk Density 150 g/l Packed Density 210 g/I pH 5.4 Particle Size Peak Value 50 pm (Laser Particle Sizer-Sympatec) Example 2 A. Cross-Linking 15 [0091]High amylose starch (30.0 kg) containing about 70% w/w of amylose (CI AmyloGel 03003) is placed in a reactor. To this reactor is added water (55.01) containing sodium hydroxide (30.0 g) and sodium sulfate (2.40 kg). The resulting slurry is heated to a temperature of 300C. Sodium trimetaphosphate (45 g) is added to the reaction mixture which is reacted for one hour. 20 B. Chemical Modification, Hydroxyproylation [0092]The crude reaction mixture from Part A is transferred into a hydroxypropylation reactor. The reaction mixture is heated to 4000. over 30 minutes and the reaction is purged with nitrogen. After a full purge, propylene oxide (1.80 kg) is added. The reaction mixture is kept at 400C. for 20 hours. The reaction mixture is neutralized 25 with 0.1N H 2
SO
4 (1:2 v/v) to a pH of 5.5. The starch slurry is washed with a basket centrifuge at a speed of 1200 rpm. The obtained starch cake is re-slurrified in 35 1 of 18 WO 2004/037222 PCT/CA2003/001638 water and centrifuged a second time. The resulting starch cake is dried in a flash dryer at an inlet temperature of 160°C. and an outlet temperature of 600 C. C. Gelatinization [0093]The modified granular starch cake is diluted in demineralized water in order to 5 form a slurry at a concentration of about 8% calculated on dry substance. The resulting slurry has a relative density of 1.032 kg/I compared to water. The pH of the modified starch slurry is adjusted to 6.0. The slurry is the heated to 1600C. by direct steam injection (Schlick Model 825). The temperature variation is not higher than ±+10C. The slurry is held in a holding column for a period of 4 minutes at a 10 temperature of 1600C. and a pressure of about 5.5 bar. The pressure is then reduced to atmospheric by passing through a flash. The slurry is then contained at 95oC. in a hold tank. D. Spray-Drying [0094]The slurry from Part C is carried out using a Niro FSD 4 spray-drying tower 15 equipped with a 0.8 mm nozzle and fed at 10 I/hour. The inlet temperature is fixed at 3000C. and the outlet temperature of 1200C. The obtained powder is a controlled release excipient with the following properties: Properties Moisture Content 5.2% Bulk Density 103 g/I Packed Density 155 g/I pH 5.3 Particle Size Peak Value 70 pm (Laser Particle Sizer-Sympatec) 20 [0095] Lubritab® is a product sold by Penwest Pharmaceuticals Co. (Cedar Rapids, IA, USA). KollidonTM SR is a product produced by BASF (Germany). Encompress T M is a dicalcium phosphate dihydrate which can be purchased from Mendell (Patterson, NY). Tramadol hydrochloride can be obtained from Chemagis Ltd., 3 Hashlosha 25 Street, P.O. Box 9091, 61090, Tel Aviv, Israel. Methods of synthesis and purification of tramadol are described in, for example, U.S. Patent Nos., 3,652,589, 5,414,129, 5,672,755, 5,874,620, 5,877,351, and 6,169,205. 19 WO 2004/037222 PCT/CA2003/001638 Manufacturing Procedure [0096]Tablets of the invention can be manufactured according to the process set out generally in the flow chart of Figure 1, and described in more detail below. [0097]Weighing: Raw materials are dispensed into clearly labeled containers. 5 [0098]Core Pre-Blend: Blend a portion of the Contramid® and Colloidal Silicon Dioxide and pass through #30 mesh screen into a suitable container. [0099]Core Blend: Place a portion of the Contramid® into a blender. Pass Tramadol Hydrochloride through a #30 mesh screen and add to blender. Rinse container with a portion of Contramid® and add to blender. Sieve Hydrogenated 10 Vegetable Oil Type I through a #30 mesh screen and add to the blender. Add the Core Pre-Blend into the blender. Add the remaining Contramid® into the blender, and blend all ingredients. Sieve the Magnesium Stearate through a #30 mesh screen and add blend with other ingredients. Dispense blend in suitable container and identify as Core Blend. 15 [00100] Dry Coated Pre-Blend: Blend a portion of the Xanthan Gum and all of the Colloidal Silicon Dioxide and pass through #30 mesh screen. [00101] Dry Coated Blend: Place a portion of the Kollidon® SR into a blender. Pass Tramadol Hydrochloride through Kason Separator with a #30 mesh screen into suitable container and add to blender. Rinse container with remaining xanthan gum 20 and add to blender. Sieve Hydrogenated Vegetable Oil Type 1 through a #30 mesh screen and add to the blender. Place Dry Coated Pre-Blend and the remainder of the Kollidon@ SR into the blender, and blend with all ingredients. Sieve the magnesium stearate through a #30 mesh screen and blend with other ingredients. Dispense granulation in suitable container and identify as Dry Coated Blend. 25 [00102] Compression: Use a Manesty Dry-Cota press to produce compression-coated tablets. Example 3 [00103] Formulations A, B, and C, as shown in Table 1, were manufactured according to the process set out above. 20 WO 2004/037222 PCTICA2003/001638 Cu coci t 00 0~ 0 N0 0 U') cc 0 U 0C C o c CM COC U. I-,' 0 0 ~Q~cJ co~~ C) CD i~ 2 C\J O0 ( 0 D0 L . O)C LO .Ocr o co~6 0 OD 6 6~ OR L o 0aC U.) WCDC 6 6 m co 'tci~ . . 0 C LL E EL *0 LL zCC) - , :a, f q- C5 0 C5-v OcoCC 30 o~~, j0IC a, -l LoC,0C, DC E o a )- a 0, E>~ w LTL U Z 0 ~ z5~ 0~ 0- 0 Ocn 2a) WO 2004/037222 PCT/CA2003/001638 Dissolution profiles of formulations A, B and C are shown in Figure 2. Tramadol Once Daily Formulation [00104] The present invention relates to a controlled release tablet composition which provides analgesic effect within 2 hours of oral administration and lasts for at 5 least 24 hours after administration. [00105] The 200 mg dose of the inventive controlled release composition surprisingly provides a rapid onset of analgesic effect within 2 hours after oral administration, and a mean tramadol plasma concentration between 100 ng/mL and 200 ng/mL for at least 24 hours after a single dose. 10 [00106] Furthermore, at steady-state, the mean tramadol plasma concentration remains between 100 ng/mL and 350 ng/mL. The inventive controlled release compositions have surprisingly been shown to provide full clinical effect for at least 24 hours after oral administration. Bioavailability Studies 15 [00107] An object of the present invention is to provide flexible dosing options for patients with different analgesic requirements, with a once daily formulation. [00108] One embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 100 mg would provide the desired early onset of action but achieve mean tramadol plasma concentrations of at 20 least 45 ng/mL between 2 and 24 hours. [00109] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 200 mg would provide the desired early onset of action but achieve mean tramadol plasma concentrations of at least 100 ng/mL between 2 and 24 hours. 25 [00110] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 300 mg would provide the desired early onset of action but achieve mean tramadol plasma concentrations of at least 150 ng/mL between 2 and 24 hours. [00111] A further embodiment of the present invention is to provide a once daily 30 formulation which upon initial ingestion of a dose of 400 mg would provide the desired early onset of action but achieve mean tramadol plasma concentrations of at least 180 ng/mL between 2 and 24 hours. 22 WO 2004/037222 PCT/CA2003/001638 [00112] further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a C'max to dose ratio of from about 0.90 to about 1.0. [00113] A further embodiment of the present invention is to provide a once daily 5 formulation which upon initial ingestion of a dose would provide a tramadol plasma concentration which rises steadily until peak tramadol concentrations are attained at a Tmax of about 4 hours to about 6 hours. Preferably, the Tmax occurs at about 5 hours to about 5.5 hours. [00114] A further embodiment of the present invention is to provide a once daily 10 formulation which upon initial ingestion of a dose would provide a tramadol plasma concentration which, after Tmax, declines in a slow but steady manner, reflecting continuing absorption in addition to elimination processes. Preferably, the decline in the tramadol plasma concentration after Tmax occurs in a log-linear fashion with a mean apparent terminal elimination half-life of between about 5.5 hours and about 15 6.5 hours. [00115] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a tramadol plasma concentration which, after Tmax, declines in a slow but steady manner, reflecting continuing absorption in addition to elimination processes, and which absorption 20 continues for at least 20 hours from the time when absorption of the ingested dose begins. [00116] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose provides a tramadol plasma concentration which, after Tmax, declines in a log-linear fashion with an apparent 25 terminal elimination rate constant (Qz) of about 0.12 h -1 . [00117] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a mean residence time (MRT) of tramadol ranging from about 15 hours to about 18 hours. [00118] A further embodiment of the present invention is to provide a once daily 30 formulation which upon initial ingestion of a dose would provide a half value duration (HVD) of tramadol which ranges from about 22.5 hours to about 25.4 hours. [00119] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a C'max to AUC 0 23 WO 2004/037222 PCT/CA2003/001638 ratio of from about 0.04 h 1 to about 0.06 h 1 '. Preferably, the C'max to AUCo- ratio is from about 0.04 h- 1 to about 0.05 h -1 . The ratio C'max/AUCo.- is used for evaluating the rate of drug absorption. [00120] A further embodiment of the present invention is to provide a once daily 5 formulation which upon initial ingestion of a dose would provide a mean AUCO- 24 with respect to the tramadol plasma concentration which increases proportionally with dose over the range of dosage strengths of 100 mg to 300 mg of the controlled release composition. [00121] A further embodiment of the present invention is to provide a once daily 10 formulation which upon initial ingestion of a dose of 100 mg would provide a mean AUC-Tmax of from about 610 ng-h/mL to about 630 ng-h/mL. [00122] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 200 mg would provide a mean AUCo-Tmax of from about 910 ng-h/mL to about 920 ng-h/mL. 15 [00123] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 300 mg would provide a mean AUCo-Tmax of from about 1570 ng-h/mL to about 1590 ng-h/mL. [00124] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose provides a mean ratio of 20 AUCO-24/AUCo.- of tramadol plasma concentration which ranges between about 70% and about 85%. Preferably, the mean ratio of AUC 0 o- 24 /AUCo- of tramadol plasma concentration ranges between about 74% and about 80%. As a result, about 15% to about 30% of the administered dose is still circulating in the plasma 24 hours post dose, depending on the dose administered. 25 [00125] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a ratio of the C'max to the dose released to the blood plasma in the first 24 hours (AUCo- 2 4/AUCo-. multiplied by the dose) of from about 1.10 to about 1.35. Preferably the ratio is from about 1.15 to about 1.31. 30 [00126] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose, would provide a ratio of the C'mrnax /TFmax to the dose administered of from about 0.10 to about 0.20. Preferably the ratio is from about 0.12 to about 0.19. 24 WO 2004/037222 PCT/CA2003/001638 [00127] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a slope in ng/ml-hr following the peak blood plasma concentration level, which does not exceed a factor of about 0.035 of the total dose administered in mg. Preferably, the factor is about 5 0.03. [00128] Tramadol pharmacokinetic parameters of the controlled release composition are presented in Table 2. 25 WO 2004/037222 PCTICA2003/001638 00 00F~ 0 C3 c - Lo LO 0 0. 't co .j (a ( 0 C, 00 ( F q L a 00 C co (al (a L6 0 ( ( h- q~ Ci (a .r. O ~ ~ ~ L 2N( CC~-( Na LO (a (a ( (D 0e N a, - C)-> m 2 't E r7 o 0 0 -D 0D IL 0O 0 0 E000 0o 02 0 0 A. 00 C.) :2 c oqc 2 ca ( co (a (a > E N- E E a E C) 0 C C) C 0n 0~ Q c 2 0 2 26 WO 2004/037222 PCT/CA2003/001638 [00129] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a ratio of the C'max calculated with respect to the blood plasma concentration of O-desmethyltramadol, to the dose of tramadol of from about 0.19 to about 0.22. Preferably the ratio is from 5 about 0.20 to 0.21. [00130] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide an O desmethyltramadol plasma concentration which rises steadily until peak tramadol concentrations are attained at a Tmax of about 8 hours to about 16 hours. 10 [00131] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide an O desmethyltramadol plasma concentration which, after Tmax, declines in a slow but steady manner, reflecting continuing tramadol absorption and subsequent metabolite formation in addition to elimination processes. Preferably, the decline in the O 15 desmethyltramadol plasma concentration occurs in a log-linear fashion with a mean apparent terminal elimination half-life of between about 6.7 hours and about 8.1 hours. [00132] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide the formation of 20 metabolite for at least 18 hours. [00133] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would, after Tmax, provide a decline in the O-desmethyltramadol plasma concentration in a log-linear fashion with an apparent terminal elimination rate constant (Xz) of about 0.1 h " 1 . 25 [00134] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a half value duration (HVD) of O-desmethyltramadol which ranges from about 25.6 hours to about 28.1 hours. [00135] A further embodiment of the present invention is to provide a once daily 30 formulation which upon initial ingestion of a dose would provide a C'max to AUC0o ratio calculated with respect to the O-desmethyltramadol plasma concentration, of about 0.04 h'. The ratio C'max/AUCo-- is used for evaluating the rate of metabolite formation. 27 WO 2004/037222 PCT/CA2003/001638 [00136] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a mean AUC 0
-
24 calculated with respect to the O-desmethyltramadol plasma concentration, which increases proportionally with dose over the range of dosage strengths of 100 mg to 5 300 mg of the controlled release composition. [00137] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 100 mg would provide a mean AUCo-Tmax with respect to the O-desmethyltramadol plasma concentration of from about 175 ng-h/mL to about 180 ng-h/mL. 10 [00138] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose of 200 mg would provide a mean AUCo-Tmax with respect to the O-desmethyltramadol plasma concentration of from about 530 ng-h/mL to about 550 ng-h/mL. [00139] A further embodiment of the present invention is to provide a once daily 15 formulation which upon initial ingestion of a dose of 300 mg would provide a mean AUCO-Tmax with respect to the O-desmethyltramadol plasma concentration of from about 580 ng-h/mL to about 590 ng-h/mL. [00140] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose provides a mean ratio of 20 AUCo- 2 4/AUCo-. of O-desmethyltramadol plasma concentration which ranges between about 65% and about 80%. Preferably, the mean ratio of AUC 0
-
2 4/AUCo.- of O-desmethyltramadol plasma concentration ranges between about 68% and about 75%. As a result, about 25% to about 32% of the active metabolite is still circulating in the plasma 24 hours post-dose. 25 [00141] A further embodiment of the present invention is to provide a once daily formulation which upon initial ingestion of a dose would provide a ratio of the C'max calculated with respect to the O-desmethyltramadol plasma concentration, to the O desmethyltramadol blood plasma concentration in the first 24 hours (AUCo.
24 /AUCo-oo multiplied by the dose of tramadol) of from about 0.0025 to about 0.0035. Preferably 30 the ratio is from about 0.0027 to about 0.0031. [00142] O-desmethyltramadol pharmacokinetic parameters of the controlled release composition are presented in Table 3. 28 WO 2004/037222 PCT/CA2003/001638 LO mD c') CD q) q C D 0 co) N~ 0) M D CD 0) N! wD m) 0 0 U E C') N l co0 0) C to~ CDq to 0 ') 0 - C 0 0 C14 Cm u cld CD Z co co 0) cl M, co Lo 0) LO 0)) co' C)ciD C 't CC -C o N- -o0 0 00) C3 6 m 06 0i 0 0 0o CD 0) U) CD 0 CD)U)~ Q 0 0 0Q 00 cm va CDN 0 ~ - Ci) ,- 29 WO 2004/037222 PCT/CA2003/001638 Example 4 (i) Dose Proportionality - Single Dose [00143] A bioavailability study was conducted to assess the dose-proportionality 5 between three dosage strengths (100 mg, 200 mg and 300 mg). This study was conducted with a suitable washout period between each administration. The doses were taken by 27 healthy human volunteers under fasting conditions. [00144] Figure 3 depicts the mean plasma concentration time-profiles of tramadol obtained in the subjects after the administration of the inventive controlled 10 release composition (dosed at 100 mg, 200 mg and 300 mg of tramadol HCI). The data used to create Figure 3 is included in Table 4. Table 4 Mean (±+SD) Tramadol Plasma Concentrations (ng/mL) 100 mg dose 200 mg dose 300 mg dose of the of the of the inventive inventive inventive Time controlled controlled controlled release release release composition composition composition 0 0 0 0 1 41.8 ± 14.1 82.5 24.1 110.2 ± 36.7 2 60.0 ± 14.6 129.2 -25.7 168.6 ± 52.1 3 69.2 ±20.2 156.5 37.0 218.1 ± 82.3 4 72.5 ± 21.8 164.0 44.9 242.0 ± 96.2 5 81.7 ± 24.2 177.2 ±61.8 277.1 ± 153.8 6 77.9 ± 24.7 169.2 58.1 260.3 ± 134.8 8 83.0 ± 25.6 164.1 ±52.7 243.6 ± 127.1 10 81.0 ± 24.7 157.8 ±57.8 219.8 ± 101.6 12 84.4 ± 25.3 156.4 55.9 223.4 ± 85.1 16 73.0 ± 24.1 152.8 42.0 209.9 ± 70.2 20 56.4 19.4 121.0 34.4 185.7 ± 62.7 24 47.2 ± 20.9 101.6 38.2 157.0 ± 60.4 30 26.8 ± 15.0 56.4 ± 28.3 99.9 ±+ 50.3 36 13.2 9.4 29.1 ± 18.7 55.9 ± 37.9 48 3.7 3.5 8.5 ± 6.7 15.7 + 13.1 15 [00145] The results from this study indicated that the 100 mg, 200 mg and 300 mg formulations of the inventive controlled release composition are dose proportional with respect to the rate and extent of absorption of tramadol and the rate and extent of formation of O-desmethyltramadol. 30 WO 2004/037222 PCT/CA2003/001638 [00146] Bioavailability studies were conducted in order to characterize the pharmacokinetic properties of the inventive controlled release composition and to demonstrate similar exposure of the drug and/or its active metabolite when compared to a reference product. 5 Example 5 (ii) Comparison to a Twice-Daily Formulation - Single Dose [00147] The 2 x 200 mg dosage of the inventive controlled release composition was compared to the twice daily formulation, TopalgicO LP (200 mg) tablets manufactured by Laboratoires Hoechst Houd6 in a comparative bioavailability study 10 after administration under fasting conditions in 24 healthy human volunteers. [00148] The pharmacokinetic results from the inventive controlled release composition were compared to those obtained following twice daily administration (at 12-hour intervals) of the reference formulation in order to assess bioequivalence between the test and the reference product. Based on calculation of the 90% 15 confidence interval of the test versus reference ratios of geometric means, the extent of exposure (determined by assessment of AUC 0 -t and AUCo.. of tramadol following dose normalization) was within the conventional bloequivalence interval of 80-125% for the log-transformed parameters. Thus the inventive controlled release composition and the twice daily formulation were found to be bioequivalent in terms 20 of the overall exposure to tramadol. Results for tramadol AUCo.. are presented in Table 5. Table 5 Comparison of AUCo. (Single-dose versus twice-daily formulation) Treatment Arithmetic Mean ± SD Geometric Mean Ratio (ng-h/mL) (90% Confidence Interval) 2 x 200 mg dose of the 9332 ±3767 9332 -3767 inventive controlled 103 (98109) release composition 1 x 200 mg 8897 ±3124 TopalgicO LP BID 25 [00149] Figure 5 depicts the arithmetic mean plasma concentration time-course profiles of tramadol obtained after the administration of the inventive controlled 31 WO 2004/037222 PCT/CA2003/001638 release composition once a day and of the reference product in one day at 12-hour intervals in the 24 healthy volunteers. The data used to create Figure 5 is included in Table 6. Table 6 5 Mean Tramadol Plasma Concentrations (nq/mL) Test formulation Reference formulation Conc. Conc. 2x200 mg dose of the inventive Time composition Time 200 mg BID 0 0 0 0 1 138.49 ± 58.62 1 101.93 ± 43.72 2 257.56 ± 81.20 2 226.89 ± 72.90 3 350.21 ± 166.42 3 296.35 ± 99.46 4 373.93 _ 124.33 4 318.22 ± 91.27 5 427.66 166.90 5 330.88 98.68 6 424.72 ± 176.20 6 281.67 ± 85.95 9 408.61 _ 196.28 9 236.39 ± 87.89 12 357.88 ±162.48 12 167.41 ± 65.49 16 312.70 ± 153.34 13 181.96 70.51 20 243.94 ± 117.93 14 284.67 ± 126.76 24 184.96 ± 102.90 15 378.82 ± 136.23 30 99.78 ± 61.60 16 396.87 ± 146.56 36 51.01 ± 43.33 17 388.83 ± 142.32 48 0 18 396.38 ±140.65 21 331.81 ±121.52 24 275.00 110.61 30 118.69 64.92 36 54.04 ± 39.07 48 0 [00150] Figure 6 depicts the arithmetic mean plasma concentration time-course profiles of O-desmethyltramadol obtained after the administration of the inventive 10 controlled release composition once-a-day and of the reference product in one day at 12-hour intervals in the 24 healthy volunteers. The data used to create Figure 6 is included in Table 7. 32 WO 2004/037222 PCT/CA2003/001638 Table 7 Mean (+±SD) O-desmethyltramadol Plasma Concentrations (ng/mL) Test formulation Reference formulation Conc. Conc. 2x200 mg dose of the inventive Time composition Time 200 mg BID 0 0 0 0 1 29.82 17.0 1 17.7 14.6 2 57.8 17.0 2 48.3 17.5 3 76.3 31.6 3 66.2 25.9 4 84.9 + 30.9 4 74.3 _ 26.2 5 98.0 + 41.4 5 80.64 _ 29.2 6 100.6 41.7 6 74.3 26.1 9 99.9 41.7 9 68.1 24.6 12 96.52 38.8 12 56.6 22.1 16 83.9 32.6 13 59.1 ± 23.8 20 68.2 28.8 14 75.1 32.6 24 57.6 ± 28.0 15 92.6 ± 38.0 30 33.2 20.0 16 96.7 37.0 36 0 17 97.0 34.5 48 0 18 100.4 33.6 21 93.0 32.4 24 83.3 37.8 30 44.4 ± 21.6 36 18.1 ± 16.8 48 0 5 Example 6 (iii) Comparison to a Twice Daily Formulation - Steady State [00151] The 200 mg dosage of the inventive controlled release composition was compared to the twice daily formulation, Topalgic@ LP (100 mg) tablets, manufactured by Laboratoires Hoechst Houde, in a comparative bioavailability study 10 after multiple administration under fasting conditions in 26 healthy human volunteers. [00152] The results from this study indicated that the inventive controlled release composition is equivalent to the reference product with respect to the rate and extent of absorption of tramadol and the rate and extent of formation of O desmethyltramadol. The comparative bioavailability of the two products was 15 assessed on the basis of the confidence interval for the primary variable AUCsS for 33 WO 2004/037222 PCT/CA2003/001638 tramadol and O-desmethyltramadol in relation to the conventional bioequivalence range of 80% to 125%. Results for tramadol AUCss are presented in Table 8. Table 8 Comparison of AUC s (Once-a-day versus twice-daily formulation) Treatment Arithmetic Mean ± SD Geometric Mean Ratio (ng-h/mL) (90% Confidence Interval) 200 mg dose of the 5185 ± 1460 inventive controlled 92.4 (87.5- 97.5) release composition Topalgic@ LP 100 mg 5538 + 1214 BID 5 [00153] Figure 7 depicts the arithmetic mean plasma concentration time-course profiles of tramadol and O-desmethyltramadol following administration of a 200 mg dose of the inventive controlled release composition once a day and of the reference product (Topalgic@ LP 100 mg BID) in one day at 12 hour intervals. The data used 10 to create Figure 7 is included in Table 9. 34 WO 2004/037222 PCT/CA2003/001638 Table 9 Mean (_SD) Tramadol and O-desmethViyltramadol Plasma Concentrations (nq/mL) Test formulation (200 mg dose of the inventive controlled release composition) Reference formulation (100 mg BID) Time Tramadol Metabolite Time Tramadol Metabolite 0 113.3 ± 48.8 37.6 9.0 0 157.8 ± 48.8 49.1 ± 10.7 1 195.4 ± 58.4 49.9 13.9 1 220.2 ± 61.1 58.1 ± 12.9 2 249.5 ± 61.0 58.9 14.4 2 251.6 ± 60.9 63.1 ± 14.6 3 285.0 ± 66.0 65.4 + 16.3 2.5 282.7 ± 65.3 68.0 ± 14.7 4 290.6 ± 65.5 66.2 - 16.0 3 290.8 ±+ 59.7 69.4 ± 15.6 5 298.9 81.1 67.3 16.7 3.5 290.9 ±70.6 69.6 ± 15.7 6 280.0 70.7 67.7 17.5 4 297.3 ± 71.3 71.3 ± 15.3 9 244.9 ± 58.4 63.9 _ 16.8 4.5 305.2 ± 75.2 72.8 ± 15.6 12 226.0 +70.2 59.8 17.2 5 281.8 ±65.5 69.1 ± 15.7 16 209.4 73.4 57.3 ± 14.8 6 262.8 ± 55.5 67.4 ± 17.3 20 161.5 68.9 47.9 12.1 7 243.9 ± 60.2 64.9 ± 15.2 24 119.9 59.1 37.1 ±8.9 9 198.0 ± 54.4 57.0 ± 12.8 12 154.6 ± 47.8 46.2 ± 10.5 13 203.5 ± 55.4 53.2 ± 12.8 14 260.7 ± 54.2 63.7 ± 15.0 14.5 307.2 ± 59.9 72.2 ± 16.5 15 303.7 ± 60.5 73.2 + 17.1 15.5 290.7 ± 54.3 71.3 ± 16.8 16 289.0 ± 54.6 72.1 ± 15.6 16.5 276.4 ± 53.2 72.1 ± 16.8 17 267.6 + 55.2 71.6 ± 16.8 18 244.6 ± 58.4 68.2 ± 15.0 19 237.1 ± 59.4 66.4 ±+ 14.8 21 201.5 ± 52.7 57.9 ± 12.0 24 156.9 ± 49.9 49.6 + 10.1 [00154] The present invention is not limited in scope by the specific 5 embodiments disclosed in these examples which are intended to illustrate the most preferred embodiments of the invention. Indeed, various modifications of the invention or other embodiments which are functionally equivalent to those shown and described herein will become apparent to those skilled in the art and are intended to be .covered by the appended claims. 10 [00155] A number of references have been cited, the entire disclosures of which are incorporated herein by reference. [00156] Although various examples of combined elements of the invention have been described, it will also be understood that these are not intended to be exhaustive and features of one embodiment may be combined with those of another, 35 WO 2004/037222 PCT/CA2003/001638 and such other combinations are contemplated to be within the scope of the invention disclosed herein. 36
Claims (32)
1. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, in which the composition, upon initial administration of one dose, provides an onset of analgesic effect within 2 hours, which 5 analgesic effect continues for at least 24 hours after administration.
2. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 100 ng/mL within 2 hours of administration and continues to provide a mean plasma 10 concentration of at least 100 ng/mL for at least 22 hours after administration.
3. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 100 ng/mL within 2 hours of administration and continues to provide a mean plasma 15 concentration of at least 100 ng/mL for at least 23 hours after administration.
4. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 100 ng/mL within 2 hours of administration and continues to provide a mean plasma 20 concentration of at least 100 ng/mL for at least 24 hours after administration.
5. The once daily oral pharmaceutical composition of claim 1, 2, 3 or 4 wherein said pharmaceutical composition comprises about 200 mg of tramadol or a salt thereof.
6. A once daily oral pharmaceutical composition for controlled release of 25 tramadol or a salt thereof comprising 100 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 50 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 50 ng/mL for at least 22 hours after administration. 37 WO 2004/037222 PCT/CA2003/001638
7. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 100 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 50 ng/mL within 2 hours of 5 administration and continues to provide a mean plasma concentration of at least 50 ng/mL for at least 23 hours after administration.
8. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a 10 mean plasma concentration of at least 150 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 150 ng/mL for at least 22 hours after administration.
9. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg of tramadol or a salt thereof, 15 wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 150 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 150 ng/mL for at least 23 hours after administration.
10. A once daily oral pharmaceutical composition for controlled release of 20 tramadol or a salt thereof comprising 300 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides a mean plasma concentration of at least 150 ng/mL within 2 hours of administration and continues to provide a mean plasma concentration of at least 150 ng/mL for at least 24 hours after administration. 25
11. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg of tramadol or a salt thereof, wherein upon initial administration of 400 mg, the composition provides a mean plasma concentration of at least 200 ng/mL for at least 22 hours after administration. 30
12. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg of tramadol or a salt thereof, 38 WO 2004/037222 PCT/CA2003/001638 wherein upon initial administration of 400 mg, the composition provides a mean plasma concentration of at least 190 ng/mL for at least 23 hours after administration.
13. A once daily oral pharmaceutical composition for controlled release of 5 tramadol or a salt thereof comprising 200 mg of tramadol or a salt thereof, wherein upon initial administration of 400 mg, the composition provides a mean plasma concentration of at least 180 ng/mL for at least 24 hours after administration.
14. The once daily oral pharmaceutical composition of claim 6 or 7 wherein the 10 mean maximum plasma concentration (Cmax) is less than 100 ng/mL.
15. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4 or 5 wherein the mean maximum plasma concentration (Cmax) is less than 300 ng/mL.
16. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4 or 5 wherein the mean maximum plasma concentration (Cmax) is less than 200 ng/mL. 15
17. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4 or 5 wherein the mean maximum plasma concentration (Cmax) is less than 2.2 times the mean plasma concentration obtained 24 hours after administration (C24h).
18. The once daily oral pharmaceutical composition of claim 8, 9 or 10 wherein the mean maximum plasma concentration (Cmax) is less than 300 ng/mL. 20
19. The once daily oral pharmaceutical composition of claim 8, 9 or 10 wherein the mean maximum plasma concentration (Cmax) is less than two times the mean plasma concentration obtained 24 hours after administration (C24h).
20. The once daily oral pharmaceutical composition of claim 11, 12 or 13 wherein the mean maximum plasma concentration (Cmax) is less than 2.3 times the 25 mean plasma concentration obtained 24 hours after administration (C24h).
21. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or20 wherein the median time to the mean maximum plasma concentration (tmax) is between 2 and 10 hours. 39 WO 2004/037222 PCT/CA2003/001638
22. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20 or 21 wherein the tmax is between 3 and 6 hours.
23. The once daily oral pharmaceutical composition of claim 1, 2, 3, 4, 5, 8, 9, 10, 5 11, 12, 13, 15, 16, 17, 18, 19, 20, 21 or 22 wherein the tmax is between 5 and 6 hours.
24. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides an 10 O-desmethyltramadol mean plasma concentration of at least 24 ng/mL within 2 hours of administration and continues to provide an O-desmethyltramadol mean plasma concentration of at least 25 ng/mL for at least 24 hours after administration.
25. A once daily oral pharmaceutical composition for controlled release of 15 tramadol or a salt thereof comprising 100 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides an O-desmethyltramadol mean plasma concentration of at least 11 ng/mL within 2 hours of administration and continues to provide an O-desmethyltramadol mean plasma concentration of at least 12 ng/mL for at least 24 hours after 20 administration.
26. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 300 mg of tramadol or a salt thereof, wherein the composition, upon initial administration of one dose, provides an O-desmethyltramadol mean plasma concentration of at least 32 ng/mL within 25 2 hours of administration and continues to provide an O-desmethyltramadol mean plasma concentration of at least 32 ng/mL for at least 24 hours after administration.
27. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof comprising 200 mg of tramadol or a salt thereof, 30 wherein upon initial administration of 400 mg, the composition provides an O desmethyltramadol mean plasma concentration of at least 50 ng/mL within 2 40 WO 2004/037222 PCT/CA2003/001638 hours of administration and continues to provide an O-desmethyltramadol mean plasma concentration of at least 50 ng/mL for at least 24 hours after administration.
28. The once daily oral pharmaceutical composition of any preceding claim, 5 wherein said composition is a tablet.
29. The formulation of any preceding claim, wherein between 10% and 40% of the agent is released from the formulation between 0 and about 2 hours of measurement, between about 30% and 60% of the agent is released from the formulation between 2 and about 7 hours of the measurement, between about 10 50% and 80% of the agent is released from the formulation between 7 and about 12 hours of measurement, and between about 80% and 100% of the agent is released from the formulation after about 20 hours of measurement.
30. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration, 15 provides an onset of analgesic effect within 2 hours, which therapeutic effect continues for at least 24 hours after administration and having a dissolution rate in vitro when measured with HPLC-USP apparatus Type 1 at 100 rpm in 50mM sodium phosphate buffer at pH 6.8, from about 5% to about 30% after 1 hour; from about 15% to about 40% after 2 hours; from about 20% to about 20 50% after 4 hours, from about 30% to about 70% after 8 hours; from about 40% to about 90% after 12 hours; from about 50% to about 100% after 16 hours; from about 60% to about 100% after 24 hours.
31. A once daily oral pharmaceutical composition for controlled release of tramadol or a salt thereof, wherein the composition, upon initial administration, 25 provides an onset of analgesic effect within 2 hours, which therapeutic effect continues for at least 24 hours after administration and having a dissolution rate in vitro when measured with HPLC-USP apparatus Type 1 at 100 rpm in 50mM sodium phosphate buffer at pH 6.8, from about 10% to about 25% after 1 hour; from about 15% to about 30% after 2 hours; from about 25% to about 30 40% after 4 hours, from about 40% to about 55% after 8 hours; from about 41 WO 2004/037222 PCT/CA2003/001638 60% to about 75% after 12 hours; from about 70% to about 90% after 16 hours; from about 90% to about 100% after 24 hours.
32. The once daily oral pharmaceutical composition of claims 30 and 31 wherein the composition comprises 200 mg of tramadol or a salt thereof. 5 42
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28102602A | 2002-10-25 | 2002-10-25 | |
US10/281,026 | 2002-10-25 | ||
US51037803P | 2003-10-10 | 2003-10-10 | |
US60/510,378 | 2003-10-10 | ||
PCT/CA2003/001638 WO2004037222A2 (en) | 2002-10-25 | 2003-10-27 | Sustained-release tramadol formulations with 24-hour efficacy |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003275855A1 true AU2003275855A1 (en) | 2004-05-13 |
AU2003275855B2 AU2003275855B2 (en) | 2009-04-23 |
Family
ID=32179487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003275855A Expired AU2003275855B2 (en) | 2002-10-25 | 2003-10-27 | Sustained-release tramadol formulations with 24-hour efficacy |
Country Status (11)
Country | Link |
---|---|
JP (1) | JP2006507277A (en) |
KR (1) | KR20050083816A (en) |
AR (1) | AR045972A1 (en) |
AU (1) | AU2003275855B2 (en) |
CA (1) | CA2503155A1 (en) |
IL (1) | IL168114A (en) |
NO (1) | NO20052479D0 (en) |
PT (1) | PT1594460E (en) |
RU (1) | RU2328275C2 (en) |
UA (1) | UA84277C2 (en) |
WO (1) | WO2004037222A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US7413749B2 (en) * | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
EP1905435A3 (en) * | 2003-03-11 | 2008-05-14 | Euro-Celtique S.A. | Titration dosing regimen for controlled release tramadol |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
MXPA06013270A (en) * | 2004-05-14 | 2007-04-23 | Johnson & Johnson | Carboxamido opioid compounds. |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
ES2389666T3 (en) * | 2005-09-09 | 2012-10-30 | Angelini Labopharm, Llc | Trazodone composition for once-daily administration |
HUE029173T2 (en) * | 2006-04-26 | 2017-02-28 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
BRPI0906467C1 (en) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | pharmaceutical dosage form with modified tear-resistant outer shape and controlled release |
LT2273983T (en) | 2008-05-09 | 2016-10-25 | Grünenthal GmbH | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
PT2293794E (en) | 2008-05-27 | 2013-07-10 | Univ Melbourne | Methods of treating mammals with eustachian tube dysfunctions |
CN107028908A (en) * | 2008-10-27 | 2017-08-11 | 阿尔扎公司 | Extended release oral acetaminophen/tramadol dosage form |
TW201105316A (en) | 2009-07-22 | 2011-02-16 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
KR101747156B1 (en) | 2009-07-22 | 2017-06-27 | 그뤼넨탈 게엠베하 | Oxidation-stabilized tamper-resistant dosage form |
CN102821757B (en) | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | By extrusion mechanism for powdery medicine compositions |
MX2013002377A (en) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt. |
RU2607499C2 (en) | 2010-09-02 | 2017-01-10 | Грюненталь Гмбх | Destruction-resistant dosage form containing anionic polymer |
EA201400172A1 (en) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES |
EA201400173A1 (en) | 2011-07-29 | 2014-06-30 | Грюненталь Гмбх | SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES |
JP6117249B2 (en) | 2012-02-28 | 2017-04-19 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Tamper resistant dosage forms comprising a pharmacologically active compound and an anionic polymer |
JP6282261B2 (en) | 2012-04-18 | 2018-02-21 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Unauthorized use and overdose prevention pharmaceutical dosage forms |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096439A1 (en) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | DOSAGE METHOD RESISTING TO INDEED USE CONTAINING ONE OR MORE PARTICLES |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
CA2917136C (en) | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
JP6480936B2 (en) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Preparation of powdered pharmaceutical composition by cryomilling |
AU2015261060A1 (en) | 2014-05-12 | 2016-11-03 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising Tapentadol |
EA201692388A1 (en) | 2014-05-26 | 2017-05-31 | Грюненталь Гмбх | DOSAGE FORM AS PARTICLE MULTIPLE, PROTECTED AGAINST CALLED DOSE RESET BY ETHANOL |
MX2017013637A (en) | 2015-04-24 | 2018-03-08 | Gruenenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction. |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
CN109310646A (en) | 2016-05-05 | 2019-02-05 | 阿奎斯蒂弗医疗股份有限公司 | Enhance the adrenaline composition of delivering |
EP3452024A1 (en) * | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
DE19530575A1 (en) * | 1995-08-19 | 1997-02-20 | Gruenenthal Gmbh | Rapidly disintegrating drug form of tramadol or a tramadol salt |
CA2270975C (en) * | 1997-07-02 | 2003-04-01 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
DE10015479A1 (en) * | 2000-03-29 | 2001-10-11 | Basf Ag | Solid oral dosage forms with delayed release of active ingredient and high mechanical stability |
US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
DE10108122A1 (en) * | 2001-02-21 | 2002-10-02 | Gruenenthal Gmbh | Medicines based on tramadol |
-
2003
- 2003-10-27 WO PCT/CA2003/001638 patent/WO2004037222A2/en active IP Right Grant
- 2003-10-27 AR ARP030103926A patent/AR045972A1/en unknown
- 2003-10-27 JP JP2004545655A patent/JP2006507277A/en active Pending
- 2003-10-27 RU RU2005115855/15A patent/RU2328275C2/en not_active IP Right Cessation
- 2003-10-27 KR KR1020057007089A patent/KR20050083816A/en not_active Application Discontinuation
- 2003-10-27 AU AU2003275855A patent/AU2003275855B2/en not_active Expired
- 2003-10-27 PT PT03809237T patent/PT1594460E/en unknown
- 2003-10-27 UA UAA200504852A patent/UA84277C2/en unknown
- 2003-10-27 CA CA002503155A patent/CA2503155A1/en not_active Abandoned
-
2005
- 2005-04-19 IL IL168114A patent/IL168114A/en active IP Right Grant
- 2005-05-23 NO NO20052479A patent/NO20052479D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20050083816A (en) | 2005-08-26 |
IL168114A (en) | 2011-05-31 |
JP2006507277A (en) | 2006-03-02 |
WO2004037222A3 (en) | 2005-09-22 |
WO2004037222A2 (en) | 2004-05-06 |
PT1594460E (en) | 2008-06-27 |
NO20052479L (en) | 2005-05-23 |
UA84277C2 (en) | 2008-10-10 |
AU2003275855B2 (en) | 2009-04-23 |
CA2503155A1 (en) | 2004-05-06 |
RU2328275C2 (en) | 2008-07-10 |
AR045972A1 (en) | 2005-11-23 |
NO20052479D0 (en) | 2005-05-23 |
RU2005115855A (en) | 2006-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003275855B2 (en) | Sustained-release tramadol formulations with 24-hour efficacy | |
US7988998B2 (en) | Sustained-release tramadol formulations with 24-hour efficacy | |
CA2489855C (en) | Sustained-release tramadol formulations with 24-hour clinical efficacy | |
US8487002B2 (en) | Controlled-release compositions | |
AU2003275854B2 (en) | Controlled-release compositions | |
AU2007234864B2 (en) | Fast release paracetamol tablets | |
AU2004312059A1 (en) | Atomoxetine formulations | |
IL104192A (en) | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient | |
CN105832687A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
ZA200504216B (en) | Sustained-release tramadol formulations with 24-hour efficacy | |
JP4897930B2 (en) | Controlled release composition | |
CN1942175B (en) | Sustained-release tramadol formulations with 24-hour efficacy | |
BRPI0315657B1 (en) | solid dosage formulation, and tablet | |
US20090162431A1 (en) | Sustained release formulations containing acetaminophen and tramadol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |